Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Completed · Phase 4

Conditions studied: Glaucoma, Ocular Hypertension

In brief

This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

Key facts

Study ID

NCT02097719

Run by

Allergan

People needed

100

Starts

2014-05-01

Expected to finish

2014-12-01

Last updated by the study team

2016-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or glaucoma that requires treatment with medication
• Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

You may not qualify if…

• History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
• History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
• Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study

Where it is running

• Study site — Racine, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.